ReviewAJNR. American journal of neuroradiology2025
Meningioma: Molecular Updates from the 2021 World Health Organization Classification of CNS Tumors and Imaging Correlates.
Review in AJNR. American journal of neuroradiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Lactoferrin and Nanotechnology: New Insights Into Glioblastoma Therapy.CNS neuroscience & therapeutics · 2026Review
- Molecular Brain Tumor Imaging Beyond [AJR. American journal of roentgenology · 2026Review
- Advanced Deep Learning Architectures in MRI-Based Brain Tumor Classification: A Systematic Review Focused on Meningiomas.Journal of imaging informatics in medicine · 2026Review
- Establishment of the H8T-MG Meningioma Cell Line and Integrated Transcriptomics Reveal a Metabolic-Immune Signature in Diploid Transitional WHO Grade 1 Tumours.Biomolecules · 2026Article
- Review
- Unlocking the full potential of MRI with artificial intelligence for pre-operative meningioma evaluation.European radiology · 2026Article
- IgG4-Related Disease Manifested as Hypertrophic Pachymeningitis: A Case Report and Literature Review.Diagnostics (Basel, Switzerland) · 2026Article
- Voxel-based spatial distribution of intracranial meningioma subtypes and their relationship to radiogenomic maps.Brain communications · 2026Article
- Adjuvant radiotherapy for WHO grade II meningiomas: the unanswered question.Frontiers in oncology · 2026Article
- Extending voxel-based lesion mapping to neurosurgical oncology: applications in intracranial meningiomas.Frontiers in oncology · 2026Article
- MUC4 and Caspase-3 Immunoexpression in Meningioma: A Histopathological Study Linking Mucin & Apoptotic Pathways.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Reproducible meningioma grading across multi-center MRI protocols via hybrid radiomic and deep learning features.Neuroradiology · 2025Article
- Comparison of adjuvant radiation versus observation and salvage radiation after subtotal resection of a WHO grade I skull base meningioma: a propensity score-adjusted analysis.Journal of neuro-oncology · 2025Article
- Real-Time Detection of Meningiomas by Image Segmentation: A Very Deep Transfer Learning Convolutional Neural Network Approach.Tomography (Ann Arbor, Mich.) · 2025Article
- Seq-ing answers: exploring meningioma biology utilizing bulk RNA-seq-based reference landscapes.Frontiers in oncology · 2025Review
- Multiphoton microscopy imaging of fibrous meningiomas based on the combination of multichannel mode and lambda mode.Frontiers in neuroscience · 2025Article
- The relationship between molecular subtypes and magnetic resonance perfusion in patients with brain meningioma.Surgical neurology international · 2025Article
- Orthotopic meningioma rat model exhibits morphological and immunohistochemical congruency and epigenetic concordance with benign primary patient-derived tumors.Scientific reports · 2024Article
- Primary intraosseous meningioma: a case of early symptomatic calvarial origin meningioma.Journal of surgical case reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Meningiomas, the most common primary intracranial neoplasms, account for more than one-third of primary CNS tumors. While traditionally viewed as benign, meningiomas can be associated with considerable morbidity, and specific meningioma subgroups display more aggressive behavior with higher recurrence rates. The risk stratification for recurrence has been primarily associated with the World Health Organization (WHO) histopathologic grade and extent of resection. However, a growing body of literature has highlighted the value of molecular characteristics in assessing recurrence risk. While maintaining the previous classification system, the 5th edition of the 2021 WHO Classification of Central Nervous System tumors (CNS5) book expands upon the molecular information in meningiomas to help guide management. The WHO CNS5 stratifies meningioma into 3 grades (1-3) based on histopathology criteria and molecular profile. The telomerase reverse transcriptase promoter mutations and cyclin-dependent kinase inhibitor 2A/B (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.